The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 3 (PCV3) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV3 infection.

Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.

Disclosed herein are methods and composition producing a viral vaccine with reduced particle size, particularly for use in the production of influenza virus vaccines.

The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coron-avirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against a SARS-CoV-2 in an individual in need thereof.

The present invention provides a vaccine against a coronavirus. According to the present invention, there is provided a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1 or a partial peptide of a coronavirus spike protein consisting of the amino acid sequence corresponding to the amino acid sequence of SEQ ID NO: 1 and a multiple antigen peptide containing a plurality of any of these peptides.

The present invention relates to an influenza virus production method using a disposable culture process system, and a test for quickly checking conditions for influenza virus antigen purification. According to the present invention, conditions for influenza surface antigen obtainment (purification) may be quickly and reliably checked according to the unique method of the present invention, even without using the single radial immunodiffusion technique which is conventionally used as a standard test method when producing influenza vaccines, and thus the production time for an influenza surface antigen subunit vaccine is notably reduced, thereby enabling quick response as a result of rapid vaccine development/manufacturing, even in a rapid novel influenza pandemic situation. In addition, according to the influenza virus production method of the present invention, culture media exchange may be carried out in an airtight system by using a continuous low-speed centrifuge using a disposable bag, and thus the possibility of contamination occurring during the virus production process may be greatly reduced.

Provided are an H5 avian influenza vaccine strain which differentiates infected from vaccinated animals, a preparation method therefor, and an application. The vaccine strain uses an NA protein of influenza B as a label, and has application value and public health significance for the prevention, control and decontamination of H5 avian influenza.

A general serum procedure for all of pathogens with protein coding on an outer shell of the pathogens, comprises entering dead pathogens and their dead genomes to eliminate pathogens and cancer genes in humans and animals. A device for detecting pathogens in human body, animals, plants, water bodies, and air without blood test observes the spectral signature emitting from the human body and the water to match for any pathogens within the device’s database and uses electrostatic properties of the pathogens and their genomes to catch them.

The present invention is directed to a pharmaceutical composition including (e.g. for use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen. The pharmaceutical composition allows for efficient induction of an adaptive immune response directed against said antigen. The present invention furthermore provides kits, as well as the use of the pharmaceutical composition or the kit as a vaccine, particularly in the treatment of infectious diseases, allergies, autoimmune diseases and tumour or cancer diseases.

The present invention relates to immunogenic immune complexes, related compositions, and related methods.